L 685393

Drug Profile

L 685393

Latest Information Update: 12 Dec 1994

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiglaucomas
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 12 Dec 1994 No-Development-Reported for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top